Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 4Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 6268Carcinoma, Renal Cell 1913Urinary Bladder Neoplasms 1670Kidney Neoplasms 930Breast Neoplasms 793Neoplasms 788Carcinoma, Transitional Cell 594Carcinoma, Non-Small-Cell Lung 524Neoplasm Metastasis 510Melanoma 485Ovarian Neoplasms 468Colorectal Neoplasms 454Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 264Non-Muscle Invasive Bladder Neoplasms 263Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 197Wilms Tumor 196Endometrial Neoplasms 189Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 146

Interventions

Androgen Antagonists 3darolutamide 2Docetaxel 2relugolix 1niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Genitourinary × Clear all
NCT07395804 2026-05-29

23146

Bayer

Recruiting
500 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07241416 2026-05-11

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
206 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06010914 2026-04-15

DADOX

Bayer

Active not recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

University of Utah

Phase 2 Recruiting
160 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡